Shares of Kura Oncology Inc (NASDAQ:KURA) have received an average recommendation of “Buy” from the thirteen research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $27.29.
Several equities research analysts have weighed in on the company. Deutsche Bank assumed coverage on Kura Oncology in a report on Thursday, July 18th. They issued a “buy” rating and a $28.00 target price for the company. Zacks Investment Research cut Kura Oncology from a “buy” rating to a “hold” rating in a report on Tuesday, September 17th. ValuEngine cut Kura Oncology from a “strong-buy” rating to a “buy” rating in a report on Saturday, October 5th. HC Wainwright reiterated a “buy” rating and issued a $29.00 target price on shares of Kura Oncology in a report on Friday, August 2nd. Finally, Wedbush reiterated a “positive” rating on shares of Kura Oncology in a report on Wednesday, September 4th.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Point72 Hong Kong Ltd purchased a new stake in shares of Kura Oncology during the 2nd quarter worth $25,000. Meeder Asset Management Inc. lifted its stake in shares of Kura Oncology by 164.9% during the 2nd quarter. Meeder Asset Management Inc. now owns 1,934 shares of the company’s stock worth $38,000 after purchasing an additional 1,204 shares during the last quarter. Bank of Montreal Can raised its stake in Kura Oncology by 82,066.7% in the second quarter. Bank of Montreal Can now owns 2,465 shares of the company’s stock valued at $49,000 after buying an additional 2,462 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Kura Oncology by 599.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,824 shares of the company’s stock valued at $56,000 after buying an additional 2,420 shares during the last quarter. Finally, Acadian Asset Management LLC purchased a new stake in Kura Oncology in the second quarter valued at about $59,000. Hedge funds and other institutional investors own 85.47% of the company’s stock.
Kura Oncology (NASDAQ:KURA) last issued its earnings results on Thursday, August 1st. The company reported ($0.38) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.41) by $0.03. Research analysts predict that Kura Oncology will post -1.61 EPS for the current fiscal year.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
See Also: Trading Penny Stocks
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.